Fosamax and Osteonecrosis of the Jaw: Causation, Risk, and What Studies Show

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Occupational Exposure Concerns

The legacy context of general health and science information has long served as a foundation for public understanding of medical risks and therapeutic benefits. Within this broad framework, discussions of pharmaceutical safety have typically centered on patient populations and clinical outcomes, drawing from established epidemiological data. As this informational heritage evolves, a natural progression emerges toward examining specific exposure scenarios that extend beyond routine clinical use. In the domain of mass production, the focus shifts from patient-centered pharmacovigilance to occupational exposure considerations. Workers involved in the manufacturing, handling, or packaging of pharmaceutical compounds may encounter distinct risk profiles that differ from those of end users. This pivot acknowledges that the same substances subject to general health scrutiny can present unique challenges in industrial settings, where exposure levels, durations, and routes may vary significantly. The transition from a general health context to an occupational exposure concern thus reframes the inquiry: rather than asking solely about patient risk, one must consider how production environments influence the potential for adverse outcomes. This perspective aligns with the broader goal of integrating occupational health into the legacy of science communication, ensuring that mass production contexts receive appropriate attention within the established informational landscape.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the occupational exposure framework, it is essential to examine specific pharmaceutical agents that have been associated with serious adverse effects. Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a known adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ involves bone exposure in the oral cavity, often with pain, swelling, and infection. Diagnosis is typically based on clinical examination and imaging, with a focus on ruling out other causes such as malignancy or radiation-induced osteonecrosis. The condition has been reported in patients taking bisphosphonates, including Fosamax and Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanisms and Risk Factors for ONJ

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current research suggests that bisphosphonates suppress bone turnover by inhibiting osteoclast activity. This suppression can impair the jawbone's ability to remodel and repair, particularly after dental procedures or in the presence of infection. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights the unique structural and cellular properties of the jawbone that may predispose it to ONJ under bisphosphonate therapy. Risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Evidence of Causation and Epidemiological Data

Causation considerations for affected patients involve assessing the temporal relationship between Fosamax use and ONJ onset, as well as the presence of other risk factors. The timeline between exposure to Fosamax and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A cohort study among female patients treated for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This study provides evidence of a dose-response relationship, with longer exposure associated with higher risk, supporting a causal link. However, the rarity of ONJ in osteoporosis patients means that individual causation must be evaluated on a case-by-case basis, considering all contributing factors.

Adequacy of Warnings and Clinical Recommendations

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific warning about ONJ, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning also lists known risk factors and advises that discontinuation of bisphosphonate treatment may reduce risk for patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label also notes that the optimal duration of use has not been determined, and for patients at low risk for fracture, consider drug discontinuation after 3 to 5 years of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, Fosamax use is associated with an increased risk of ONJ, particularly with longer duration of use and in the presence of other risk factors such as invasive dental procedures. The prescribing information includes warnings about this risk, and patients should be counseled on preventive dental care and the potential need for drug discontinuation before dental procedures. The evidence from clinical studies and epidemiological data supports a causal relationship, though absolute risks remain low.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ) and how is it related to Fosamax?

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, often associated with tooth extraction or local infection. Fosamax (alendronate), a bisphosphonate used for osteoporosis, has been linked to ONJ as a known adverse effect. The risk increases with longer duration of use and in the presence of other risk factors such as invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What does the research say about the risk of ONJ from Fosamax?

Epidemiological studies show a dose-response relationship: a cohort study found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use, though absolute risks remain low (approximately 0.05% after 5 years) (https://pubmed.ncbi.nlm.nih.gov/39400702/). The risk diminishes after discontinuation. Mechanistic research suggests bisphosphonates suppress bone turnover, impairing jawbone repair (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Are there adequate warnings about ONJ for Fosamax users?

Yes, the prescribing information for Fosamax includes a specific warning about ONJ, listing risk factors and advising discontinuation before invasive dental procedures when possible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the label also notes that the optimal duration of use has not been determined, and for low-risk patients, discontinuation after 3-5 years may be considered.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.